CoChat

223Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice

Open access
Dizdarevic, Sabina, Jessop, Maryam, Begley, Patrick, Main, Sean, Robinson, Angus · 2018 · European Journal of Nuclear Medicine and Molecular Imaging

The DOI matches its Crossref record; 19 of the 20 references it cites were found in a registry or an index.

Abstract

We first assessed whether the pattern of referrals to a nuclear medicine clinic improved as experience with 223 Ra-dichloride increased, and whether referral patterns affected patient outcomes, and second assessed the value of bone scintigraphy, total alkaline phosphatase (tALP) and lymphadenopathy as prognostic factors in patients receiving 223 Ra-dichloride. A total of 57 patients eligible to receive 223 Ra-dichloride over a 2-year period (March 2014 to March 2016) were retrospectively assessed and prospectively followed (median follow up 298 days). 223 Ra-Dichloride was administered at 4-week intervals for a maximum of six injections. The numbers of patients in years 1 and 2 referred in relation to extent of bone disease (EOBD) category and overall survival (OS) were determined. The prognostic factors EOBD category, baseline tALP (tALP BL ), tALP response, greatest percentage reduction in tALP from baseline in any treatment cycle (ALP max ; among patients with elevated ALP BL ), and the presence of lymphadenopathy were assessed as predictors of OS. The proportion of patients with EOBD1 was higher in year 2 than in year 1 (29% and 4%, respectively), and in year 2 there was a lower rate of symptomatic skeleton-related events, a higher proportion of patients completing six cycles, and longer (albeit nonsignificant) OS ( p = 0.55). There were significant differences in OS between EOBD4 patients and those in all other groups and between EOBD1 and EOBD3 patients ( p < 0.05). OS was longer in patients with normal tALP BL than in those with elevated tALP BL ( p = 0.01), in ALP responders than in nonresponders ( p < 0.05), and in patients without lymphadenopathy than in those with lymphadenopathy ( p = 0.29). OS was correlated with ALP max ( r 2 = 0.24). A collaborative multidisciplinary referrals pathway, together with increased experience with 223 Ra-dichloride, led to improved outcomes. In patients with elevated tALP BL , tALP dynamics may be useful for monitoring response and predicting OS. Imaging and prognostic markers may therefore be of value for individualizing 223 Ra-dichloride treatment and planning retreatment; however, further studies are required.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-018-4083-3

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Pattern of referrals from uro-oncology to nuclear medicine in year 1 and year 2, in relation to the extent of bone disease (EOBD) category among the 57 included patients
Fig. 1 Pattern of referrals from uro-oncology to nuclear medicine in year 1 and year 2, in relation to the extent of bone disease (EOBD) category among the 57 included patientsCC BY · PubMed Central
Fig. 2 Overall survival in 26 patients in year 1 and 31 patients in year 2. Median survival times: 233 days in the total population, 227 days in year-1 patients, and 266 days in year-2 patients. Median follow-up times: 298 days in the total population, 234 days in year-1 patients, and 363 days in year-2 patients (p = 0.55, year 1 vs. year 2)
Fig. 2 Overall survival in 26 patients in year 1 and 31 patients in year 2. Median survival times: 233 days in the total population, 227 days in year-1 patients, and 266 days in year-2 patients. Median follow-up times: 298 days in the total population, 234 days in year-1 patients, and 363 days in year-2 patients (p = 0.55, year 1 vs. year 2)CC BY · PubMed Central
Fig. 3 Overall survival in relation to extent of bone disease (EOBD) category: 10 patients with EOBD1, 16 with EOBD2, 17 with EOBD3 and 14 with EOBD4. Median survival times: 437 days, 242 days, 250 days, and 116 days in patients with EOBD1, EOBD2, EOBD3 and EOBD4, respectively. Median follow-up times: 485 days, 359 days, 278 days, and 116 days, respectively. *p < 0.05 vs. EOBD4
Fig. 3 Overall survival in relation to extent of bone disease (EOBD) category: 10 patients with EOBD1, 16 with EOBD2, 17 with EOBD3 and 14 with EOBD4. Median survival times: 437 days, 242 days, 250 days, and 116 days in patients with EOBD1, EOBD2, EOBD3 and EOBD4, respectively. Median follow-up times: 485 days, 359 days, 278 days, and 116 days, respectively. *p < 0.05 vs. EOBD4CC BY · PubMed Central
Fig. 4 Overall survival in relation baseline alkaline phosphatase (ALPBL) status (normal in 16 patients, elevated in 40; one patient did not have any baseline data). Median survival times: 401 days in patients with normal ALPBL, and 222 days in those with elevated ALPBL. Median follow-up times: 468 days in patients with normal ALPBL, and 234 days in those with elevated ALPBL. ,. *p = 0.01 vs. normal ALPBL
Fig. 4 Overall survival in relation baseline alkaline phosphatase (ALPBL) status (normal in 16 patients, elevated in 40; one patient did not have any baseline data). Median survival times: 401 days in patients with normal ALPBL, and 222 days in those with elevated ALPBL. Median follow-up times: 468 days in patients with normal ALPBL, and 234 days in those with elevated ALPBL. ,. *p = 0.01 vs. normal ALPBLCC BY · PubMed Central
Fig. 5 Overall survival in relation to alkaline phosphatase (ALP) response (≥30% vs. <30% reduction from baseline; 30 responders, 26 nonresponders). Median survival times: 363 days in ALP responders, and 115 days in ALP nonresponders. Median follow-up times: 411 days in ALP responders, and 170 days in ALP nonresponders. *p = 0.01 vs. ALP responders
Fig. 5 Overall survival in relation to alkaline phosphatase (ALP) response (≥30% vs. <30% reduction from baseline; 30 responders, 26 nonresponders). Median survival times: 363 days in ALP responders, and 115 days in ALP nonresponders. Median follow-up times: 411 days in ALP responders, and 170 days in ALP nonresponders. *p = 0.01 vs. ALP respondersCC BY · PubMed Central
Fig. 6 Overall survival in relation to alkaline phosphatase (ALP) response among patients with elevated total ALP at baseline (≥10% vs. <10% reduction from baseline; 34 responders, 6 nonresponders). Median survival times: 256 days in ALP responders, and 137 days in ALP nonresponders. Median follow-up times: 325 days in ALP responders, and 216 days in ALP nonresponders. *p = 0.03 vs. ALP responders
Fig. 6 Overall survival in relation to alkaline phosphatase (ALP) response among patients with elevated total ALP at baseline (≥10% vs. <10% reduction from baseline; 34 responders, 6 nonresponders). Median survival times: 256 days in ALP responders, and 137 days in ALP nonresponders. Median follow-up times: 325 days in ALP responders, and 216 days in ALP nonresponders. *p = 0.03 vs. ALP respondersCC BY · PubMed Central
Fig. 7 Correlation between overall survival and greatest percentage reduction in total alkaline phosphatase (tALP) from baseline in any treatment cycle (ALPmax) among 40 patients with elevated tALP at baseline (r2 = 0.24)
Fig. 7 Correlation between overall survival and greatest percentage reduction in total alkaline phosphatase (tALP) from baseline in any treatment cycle (ALPmax) among 40 patients with elevated tALP at baseline (r2 = 0.24)CC BY · PubMed Central
Fig. 8 Overall survival in relation to the presence lymph node disease (13 patients with lymph node disease, 30 patients without). Median survival times: 181 days in those with lymph node disease, and 325 days in those without lymphadenopathy at any stage. Median follow-up times: 221 days in those with lymph node disease, and 371 days in those without lymphadenopathy at any stage. p = 0.29 for presence vs. absence of lymph node disease
Fig. 8 Overall survival in relation to the presence lymph node disease (13 patients with lymph node disease, 30 patients without). Median survival times: 181 days in those with lymph node disease, and 325 days in those without lymphadenopathy at any stage. Median follow-up times: 221 days in those with lymph node disease, and 371 days in those without lymphadenopathy at any stage. p = 0.29 for presence vs. absence of lymph node diseaseCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 3

  1. 16. Gayed I, Canfield S, Fanous M, Wan D, Joseph U, Amato R. Optimizing patient selection for therapy with radium 223 dichloride. J Nucl Med. 2017;57:2016-7.
  2. 19. Fontana A, Delmas P. Markers of bone turnover in bone metastases. Cancer. 2000;88:2952-60. · doi:10.1002/1097-0142(20000615)88:12+<2952::aid-cncr11>3.0.co;2-m
  3. 27. Kulkarni H, Singh A, Baum R. Differential response of bone versus lymph node metastases after Lu-177 labelled PSMA radioligand therapy in patients with metastatic castration-resistant prostate can- cer. Eur J Nucl Med Mol Imaging. 2016;43:S37.

Cited by

Metadata

Authors
Dizdarevic, S., Jessop, M., Begley, P., Main, S., & Robinson, A.
Affiliations
  • Brighton and Sussex Medical School (GB)
  • Brighton and Sussex University Hospitals NHS Trust (GB)
Corresponding author
Dizdarevic, Sabina
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2018-07-11
Volume
45
Issue
13
Pages
2264-2273
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2839363354
Cited by
29
References
20
Citations by year
2026: 1 · 2025: 6 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 5 · 2019: 3
FWCI
2.45
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Bayer HealthCare (N/A)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
Keywords
radium-223, castration-resistant prostate cancer, metastatic prostate cancer, overall survival, prognostic factors, total alkaline phosphatase, bone scintigraphy, lymphadenopathy, treatment response monitoring, bone metastasis, clinical experience, personalized treatment
MeSH terms
Aged, Aged, 80 and over, Alkaline Phosphatase, Humans, Male, Middle Aged, Neoplasm Metastasis, Radioisotopes, Radium, Retrospective Studies, Survival Analysis, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.